Nexus Pharmaceuticals, LLC has announced its receipt of approval from the U.S. Food and Drug Administration (FDA) for Fluorescein Injection, USP.

Usman Ahmed, President and Chief Executive Officer of Nexus Pharmaceuticals, expressed enthusiasm about this FDA approval, stating, "Receiving FDA approval for Fluorescein Injection is another exciting step made towards addressing a supply shortfall of a critical medication on the FDA drug shortage list. Nexus stands ready to continue to be part of the solution in the battle against drug shortages."

Fluorescein Injection, USP 10% is available in cartons containing ten 5 mL Single-dose Vials.

Fluorescein Injection, USP 10% is a sterile solution primarily used for diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.

Nexus Pharmaceuticals, LLC is a U.S.-based healthcare company specializing in innovative processes for manufacturing specialty and generic drugs. The company's focus is on making these drugs easier to use, less labor-intensive, and more streamlined in practice. Nexus Pharmaceuticals is committed to producing high-quality FDA-approved drugs that fulfill critical unmet medical needs, ensuring dependable life-saving treatment options are available when and where needed.